Compare SBET & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | SANA |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2025 | 2021 |
| Metric | SBET | SANA |
|---|---|---|
| Price | $6.28 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $18.71 | $7.80 |
| AVG Volume (30 Days) | ★ 6.3M | 3.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $105.19 | N/A |
| Revenue Next Year | $13.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $5.96 | $1.98 |
| 52 Week High | $124.12 | $6.55 |
| Indicator | SBET | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 42.42 |
| Support Level | $6.05 | $3.03 |
| Resistance Level | $8.20 | $3.43 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 9.37 | 23.81 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.